Chemoinformaics analysis of ent-17-Norkauran-16-one
| Molecular Weight | 274.448 | nRot | 0 |
| Heavy Atom Molecular Weight | 244.208 | nRig | 20 |
| Exact Molecular Weight | 274.23 | nRing | 4 |
| Solubility: LogS | -3.983 | nHRing | 0 |
| Solubility: LogP | 5.14 | No. of Aliphatic Rings | 4 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 4 |
| Atoms Count | 50 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 20 | No. of Aromatic Carbocycles | 0 |
| nHetero | 1 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 2 | No. Saturated Carbocycles | 4 |
| No. of Hydrogen atom | 30 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 19 | No. of Saturated Rings | 4 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 1 | No. of Arom Bond | 0 |
| nHA | 1 | APOL | 52.5358 |
| nHD | 0 | BPOL | 30.9642 |
| QED | 0.608 |
| Synth | 5.278 |
| Natural Product Likeliness | 2.915 |
| NR-PPAR-gamma | 0.011 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Rejected |
| Golden Triangle | Accepted |
| Pgp-inh | 0.921 |
| Pgp-sub | 0.001 |
| HIA | 0.003 |
| CACO-2 | -4.794 |
| MDCK | 0.0000132 |
| BBB | 0.444 |
| PPB | 0.855776 |
| VDSS | 1.193 |
| FU | 0.0865786 |
| CYP1A2-inh | 0.071 |
| CYP1A2-sub | 0.319 |
| CYP2c19-inh | 0.107 |
| CYP2c19-sub | 0.861 |
| CYP2c9-inh | 0.268 |
| CYP2c9-sub | 0.231 |
| CYP2d6-inh | 0.032 |
| CYP2d6-sub | 0.801 |
| CYP3a4-inh | 0.85 |
| CYP3a4-sub | 0.272 |
| CL | 18.424 |
| T12 | 0.141 |
| hERG | 0.053 |
| Ames | 0.01 |
| ROA | 0.812 |
| SkinSen | 0.46 |
| Carcinogencity | 0.902 |
| EI | 0.137 |
| Respiratory | 0.969 |
| NR-Aromatase | 0.087 |
| Antiviral | No |
| Prediction | 0.668765 |